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Background: Inflammation plays a key role in modulating cardiovascular (CV) risk. Rheumatoid arthritis (RA) patients treated with the 
interleukin-6 receptor inhibitor tocilizumab have marked reductions in C-reactive protein but modest increases in lipid parameters. The relative 
contributions of inflammation and lipids to CV risk in this population have not been fully defined.
Methods: Data were compared from RA patients with (n = 50) and without (n = 3936) major adverse cardiovascular events (MACE) in tocilizumab 
phase 3 trials. Univariate Cox proportional hazards modeling was used to evaluate MACE risk factors at baseline, after 24 weeks of tocilizumab 
treatment and changes from baseline to 24 weeks with time to MACE as the time variable; multivariate Cox proportional hazards models were fit to 
obtain best prediction of time to MACE.
Results: Univariate modeling showed baseline age, prior cardiac disorders, statin use, RA disease activity score (DAS28), total cholesterol/high-
density lipoprotein ratio, apolipoprotein-B and apolipoprotein-B/apolipoprotein-A1 ratio as predictive of MACE on tocilizumab. Baseline age, history 
of prior cardiac disorders, DAS28, and total cholesterol/high-density lipoprotein ratio were robust predictors of MACE in multivariate modeling. Post-
treatment decreases in inflammation markers and lipid increases up to week 24 did not predict future MACE. However, higher levels of RA disease 
activity measures: swollen joints (hazard ratio [HR] [95% CI]=1.092 [1.051-1.136], p<0.0001) and DAS28 (HR=1.351 [1.118, 1.633], p=0.0018) 
at week 24 were associated with increased risk of future MACE.
Conclusion: Baseline traditional CV risk factors (age and lipid/atherogenic indices) as well as RA disease activity measures are predictive of MACE 
in RA patients on tocilizumab. Lipid increases observed on tocilizumab therapy do not appear to confer increased CV risk, whereas reductions in RA 
disease activity lowered CV risk. Taken together, these data suggest that efforts aimed at aggressive screening and treatment of traditional CV risk 
factors combined with lowering of RA disease activity may be a means of lowering risk of MACE in this population.
